Novocure (NVCR) - Stock Price & Dividends
Exchange: USA Stocks • Country: Jersey • Currency: USD • Type: Common Stock • ISIN: JE00BYSS4X48
NovoCure Limited, traded on NASDAQ as NVCR, is a company dedicated to oncology. They focus on creating, manufacturing, and selling devices known as tumor treating fields (TTFields) for treating various solid tumor cancers worldwide.
One of their notable products is Optune, designed to help combat glioblastoma, a type of brain tumor. Another device they offer is Optune Lua, specifically formulated for treating malignant pleural mesothelioma.
NovoCure has an extensive portfolio of ongoing and completed clinical trials exploring the efficacy of TTFields in a range of cancers, such as brain metastases, gastric cancer, liver cancer, and more. This research underscores their commitment to finding innovative cancer treatment solutions beyond traditional methods.
Established in 2000, NovoCure is headquartered in Saint Helier, Jersey, and operates in key markets including the United States, Europe, the Middle East, Africa, Japan, and Greater China. To learn more about NovoCure and their impactful work, visit their official website at https://www.novocure.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
NVCR Stock Overview
| Market Cap in USD | 1,295m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC SubIndustry | Health Care Equipment |
| TER | 0.00% |
| IPO / Inception | 2015-10-02 |
NVCR Stock Ratings
| Growth 5y | -4.84 |
| Fundamental | -68.9 |
| Dividend | - |
| Rel. Performance vs Sector | -17.14 |
| Analysts | 3.83/5 |
| Fair Price Momentum | 9.32 USD |
| Fair Price DCF | - |
NVCR Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
NVCR Growth Ratios
| Growth 12m | -80.22% |
| Growth Correlation 12m | -60% |
| Growth Correlation 3m | -29% |
| CAGR 5y | -23.09% |
| Sharpe Ratio 12m | -1.00 |
| Alpha vs SP500 12m | -112.62 |
| Beta vs SP500 5y weekly | 1.29 |
| ValueRay RSI | 42.09 |
| Volatility GJR Garch 1y | 78.16% |
| Price / SMA 50 | -17.51% |
| Price / SMA 200 | -33.37% |
| Current Volume | 839.7k |
| Average Volume 20d | 1752.2k |
External Links for NVCR Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 24, 2024, the stock is trading at USD 12.06 with a total of 839,660 shares traded.
Over the past week, the price has changed by -3.25%, over one month by -8.74%, over three months by -14.87% and over the past year by -80.91%.
According to ValueRays Forecast Model, NVCR Novocure will be worth about 10.2 in April 2025. The stock is currently trading at 12.06. This means that the stock has a potential downside of -15.26%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 27.3 | 127 |
| Analysts Target Price | 56.6 | 369 |
| ValueRay Target Price | 10.2 | -15.3 |